SAB Biotherapeutics President and CEO Eddie J. Sullivan, PhD, Featured on COVID-19 Panel at BIO Digital 2020
June 8, 2020SIOUX FALLS, S.D.–(BUSINESS WIRE)–#COVID19–SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a proprietary technology to produce fully human polyclonal antibodies without the need for human plasma donors, today announced Eddie J. Sullivan, PhD, President, CEO and Co-founder of SAB Biotherapeutics will serve an expert panelist during BIO Digital 2020. The BIO International Convention, which has transitioned to a new and virtual event and has been renamed BIO Digital.
The Panel: “Leveraging Innovative Technology to Treat COVID-19 Patients”, will take place Monday, June 8, 2020 from 10:30 AM to 11:45 AM PDT.
The event will be moderated by Phyllis Arthur, Vice President, Infectious Diseases and Diagnostics Policy, Biotechnology Innovation Organization. Announced speakers include: Julie Kim, President, Plasma-Derived Therapeutics Business Unit, Takeda; George Scangos, PhD, Chief Executive Officer and Director, Vir Biotechnology, Inc.; Gil Van Bokkelen, PhD, Founder, Chairman and CEO, Athersys, Inc.; and George Yancopoulos, MD, PhD, Co-Founder, President & Chief Scientific Officer, Regeneron.
|
Event: |
||
|
Panel Summary: |
As the consequences of COVID-19 infection have been felt around the world, companies moved swiftly to test many of the products in their pipelines against SARS CoV2, the virus that causes COVID-19, as well as the complex set of complications associated with the virus. This has led to a broad array of novel approaches to treating patients infected with the virus, from antibodies that could be given as prevention or treatment to products that help reduce the impact of the cytokine storm and treat Acute Respiratory Distress Syndrome (ARDS), severe inflammation, and secondary bacterial infections. This panel of top scientists and industry leaders will share information on the development of these vital treatment options and how partnerships between industry, governments and NGOs will help speed the availability of new medicines that benefit patients. |
|
|
Panel: |
||
|
Presentation Date: |
10:30 AM – 11:45 AM (PDT), Monday, June 8, 2020 |
|
|
Link to BIO Partnering: |
About BIO:
BIO is the world’s largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.
About SAB Biotherapeutics, Inc.:
SAB Biotherapeutics, Inc. (SAB) is a clinical-stage, biopharmaceutical company advancing a new class of immunotherapies leveraging fully human polyclonal antibodies. Utilizing some of the most complex genetic engineering and antibody science in the world, SAB has developed the only platform that can rapidly produce natural, highly-targeted, high-potency, human polyclonal immunotherapies at commercial scale. SAB-185, a fully-human polyclonal antibody therapeutic candidate for COVID-19, is being developed in collaboration with CSL Behring and initial funding up to $9.4 million supported by the Biomedical Advanced Research Development Authority (BARDA), part of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services through an existing Rapid Response contract with the Department of Defense (DoD) Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO – CBRND) Joint Project Lead for Enabling Biotechnologies (JPL-EB). The company is advancing programs in autoimmunity, infectious diseases, inflammation and oncology. For more information visit: www.sabbiotherapeutics.com or follow @SABBantibody on Twitter.
Contacts
Melissa Ullerich
Tel: 605-679-4609
[email protected]
Media
Sean Leous
Tel: 646-866-4012
[email protected]